Sort   by:  
 Page size 
ProteomicsMapping the Interactome of KRAS and Its G12C/D/V Mutants by Integrating TurboID Proximity Labeling with Quantitative Proteomics
RAS is one of the most frequently mutated proto-oncogenes in human malignancies, with mutation sites and subtypes exhibiting tumor-type dependent distribution. Oncogenic RAS mutations will maintain continuously GTP-bound activation states that leading to dysregulation of downstream signaling, ultima...
ORGANISM(S): Homo sapiens (Human) 
2025-06-09 | PXD062101 | Pride
Kras interactome  kras g12 mutants  turboid proximity-labeling  quantitative proteomics；metabolic reprogramming 
GenomicsExpression analysis in plasma sample from KRAS G12C–mutant patients monitoring during treatment with KRAS G12C inhibitors
Expression analysis in plasma sample from KRAS G12C–mutant patients monitoring during treatment with KRAS G12C inhibitors
PRJNA1427219 | ENA
MetabolomicsTargeting GSTZ1 sensitizes KRASG12C-mutant lung cancer cells by overcoming glutathione and glycolysis pathway rewiring

KRAS mutations are prevalent in lung cancer, but KRAS G12C inhibitors exhibit limited efficacy, partly due to metabolic adaptations, such as enhanced glutathione metabolism and increased glycolysis. Glutathione S-Transferase Zeta 1 (GSTZ1) is a metabolic enzyme that regulates cell metabolism. How...

2026-05-15 | MTBLS12791 | MetaboLights
GenomicsExpression analysis of baseline tissue samples from KRAS G12C–mutant patients and longitudinal blood monitoring during treatment with KRAS G12C inhibitors
Expression analysis of baseline tissue samples from KRAS G12C–mutant patients and longitudinal blood monitoring during treatment with KRAS G12C inhibitors
PRJNA1427230 | ENA
GenomicsAURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C -mutant NSCLC
AURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C -mutant NSCLC
PRJNA1404127 | ENA
ProteomicsDynamic conformational equilibria in the active states of KRas and NRas
The design of potent RAS inhibitors benefits from a molecular understanding of the dynamics in KRAS and NRAS and their oncogenic mutants. Here we characterize switch-1 dynamics in GTP-state KRAS and NRAS by 31P NMR, by 15N relaxation dispersion NMR, hydrogen-deuterium exchange mass spectrometry (HDX...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD054924 | Pride
Ras inhibitors  nras  kras  hdx-ms  hydrogen/deuterium exchange mass spectrometry  oncogenic mutants 
GenomicsEffects of KRAS G12C and SHP2 inhibitors on drug-resistant subpopulations
Effects of KRAS G12C and SHP2 inhibitors on drug-resistant subpopulations
PRJEB101588 | ENA
GenomicsKRAS G12C inhibition combined with CD47 and immune checkpoint blockage overcomes intrinsic resistance to concomitant KRAS G12C and immune checkpoint inhibitor therapy
KRAS G12C inhibition combined with CD47 and immune checkpoint blockage overcomes intrinsic resistance to concomitant KRAS G12C and immune checkpoint inhibitor therapy
PRJNA1234660 | ENA
GenomicsCharacterization of cell lines derived from KPAR1.3 tumours resistant to KRAS G12C inhibitors
mouse lung tumor cell lines resistant to KRAS G12C inhibitor adagrasib
PRJEB101476 | ENA
ProteomicsCovalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
The discovery of KRAS G12C inactive state inhibitors represents a significant advancement in the field of precision oncology. While inactive state inhibition shows promise in patients, SWII-binding inhibitors targeting both inactive and active states remain an underdeveloped therapeutic modality. H...
ORGANISM(S): Homo sapiens (Human) 
2025-11-04 | PXD062227 | Pride
Sort   by:  
 Page size